(Reuters) - Drugmaker Vectura Group Plc (VEC.L) said its asthma therapy Flutiform had not met the primary endpoint in a late-stage trial to determine its ability to treat COPD, a type of lung disease, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results